A-ha singer Morten Harket diagnosed with Parkinson's disease
In a statement on the band's website, and confirmed by record label Sony Music, Harket, 65, said he had undergone several rounds of brain surgery and that he was managing the symptoms of the disease.
Parkinson's causes deterioration in the brain's nervous system, leading to tremors and other symptoms that can become progressively worse over time. The disease can be treated with surgery and medication, but there is no cure.
Harket said he last year underwent neurological procedures to have electrodes implanted inside his brain and that this had reduced the symptoms.
Known for the wide range of his voice, Harket said he did not know if he would be able to perform again.
"I've got no problem accepting the diagnosis," he said, adding that it was difficult to balance medication and managing side effects of the treatment.
"I'm trying the best I can to prevent my entire system from going into decline," Harket said.
Formed in 1982 by Harket and his friends Paul Waaktaar-Savoy and Magne Furuholmen, a-ha saw a global breakthrough in 1985 with their debut album Hunting High and Low which yielded several hits such as Take On Me and The Sun Always Shines on TV.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
4 days ago
- CTV News
What to know about Parkinson's disease after Ozzy Osbourne's death
Flowers and messages are left by fans to commemorate the death of Ozzy Osbourne at the Black Sabbath Bridge in Birmingham, Wednesday, July 23, 2025. (AP Photo/Kin Cheung) Heavy metal rocker Ozzy Osbourne died this week at 76, just weeks after his farewell show and about five years after announcing he had Parkinson's disease. Here's what to know about the disease: What is Parkinson's? Parkinson's is a neurologic disease that robs people of control over their movements. It typically starts with tremors and is characterized by slow movement, a shuffling gait, stiff limbs, balance problems and slurred speech. Who gets it? About one million Americans are living with Parkinson's, and 10 million people worldwide, the Parkinson's Foundation. estimates. It usually appears after age 60, although sometimes it can develop before age 50. What causes Parkinson's? The exact cause isn't known, but Parkinson's develops when cells that produce one of the brain's chemical messengers, called dopamine, begin to deteriorate and die. Dopamine transports signals to parts of the brain that control movement. Parkinson's symptoms appear after enough dopamine-producing cells die that there's too little of this neurotransmitter in the brain. According to the foundation, most experts believe genetic and environmental factors are behind the disease. Dozens of gene mutations linked to Parkinson's have been discovered and genetics account for 10 per cent to 15 per cent of all cases. Other factors suspected of increasing the risk include head injuries, exposure to pesticides and herbicides and where you live. Is there a cure? There is no cure but there are treatments, including medications that affect dopamine levels and a surgically implanted tremor-blocking device. Patients also can benefit from physical and occupational therapy. What's the prognosis? Symptoms worsen over time, usually slowly. The severity of symptoms and how quickly they progress varies widely between patients. In advanced cases, people may be unable to walk or care for themselves. They also can suffer from depression as well as memory and thinking problems. While Parkinson's itself isn't considered fatal, people can die from complications of the disease, including lung problems as muscle weakness impedes the ability to cough and to swallow. The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. The Associated Press
Globe and Mail
6 days ago
- Globe and Mail
How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings?
AbbVie ABBV holds a leadership position in the neuroscience space, which encompasses blockbuster medications such as Botox Therapeutic and depression drug Vraylar. Over the years, the company has further expanded this franchise to now include oral migraine drugs Qulipta and Ubrelvy and, most recently, Vyalev (for Parkinson's disease). Sales from the neuroscience segment accounted for over 17% of AbbVie's first-quarter revenues, which grew 16% year over year. Our model estimates second-quarter 2025 sales for the overall neuroscience franchise to be $2.5 billion, representing around 15% year-over-year growth. Higher sales of Botox Therapeutic and Vraylar are likely to have contributed to growth during the quarter. Sales of Ubrelvy and Qulipta might have benefited from market share gains across their respective approved indications. While Vyalev was recently launched in the United States and is expected to have delivered modest domestic revenues in the second quarter, the drug is already approved in several international markets. As such, a majority of Vyalev's second-quarter sales are likely to have come from ex-U.S. regions. Though AbbVie's neuroscience portfolio continues to grow meaningfully, investor focus will largely remain on its immunology franchise, which houses three flagship drugs — Humira, Rinvoq and Skyrizi. All eyes will be on the magnitude of their sequential growth and market share gains when the company reports second-quarter results on July 31. Competition in the Neuroscience Space Other bigger players in this space are Biogen BIIB and Johnson & Johnson JNJ. Despite the steeply declining revenues of its multiple sclerosis franchise, Biogen generates more than half of its top line from neuroscience therapies. BIIB is one of the handful of companies that markets an FDA-approved treatment for Alzheimer's disease (AD), Leqembi, in partnership with Eisai. Biogen also markets Zurzuvae, the first and only FDA-approved oral treatment for postpartum depression (PPD). While not competing with Biogen directly in the neuroscience space, AbbVie is actively developing AD therapies as part of its neuroscience expansion strategy. J&J markets several leading neuroscience products, led by the blockbuster antidepressant nasal spray Spravato and antipsychotic drug Invega Sustenna. Both remain key growth drivers for the company's pharma unit. In April, J&J closed the acquisition of Intra-Cellular Therapies, which added antidepressant drug Caplyta to its neuroscience portfolio. While already approved for schizophrenia and bipolar depression, a regulatory filing is under FDA review for the drug in a third indication — major depressive disorder — with a regulatory decision expected later this year. ABBV's Price Performance, Valuation and Estimates Shares of AbbVie have outperformed the industry year to date, as shown in the chart below. From a valuation standpoint, AbbVie is not very cheap. Based on the price/earnings (P/E) ratio, the company's shares currently trade at 14.06 times forward earnings, a tad lower than its industry's average of 14.60. The stock is cheaper than some other large drugmakers, such as Eli Lilly and Novo Nordisk, but priced much higher than most other large drugmakers. The stock is currently trading above its five-year mean of 12.55. While the EPS estimates for 2025 have declined from $12.32 to $11.98, the same for 2026 have increased from $14.06 to $14.08 over the past 30 days. AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report
CBC
04-07-2025
- CBC
Halifax dance classes for people with Parkinson's raise strength, spirits
Dance to Move offers free classes for people with Parkinson's and their caregivers. The dance classes help with mobility, balance, strength and the well-being of participants.
